CAM
GANX icon

Cresset Asset Management’s Gain Therapeutics GANX Stock Holding History

Cresset Asset Management’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$325K Hold
160,000
– – ﹤0.01% 1350
2026
Q1 		$310K Hold
160,000
– – ﹤0.01% 1250
2025
Q4 		$515K Buy
+160,000
New +$427K ﹤0.01% 1054

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Cresset Asset Management's GANX Position: Q2 2026 in Review

Cresset Asset Management held its Gain Therapeutics (GANX) position steady in Q2 2026 at 160,000 shares worth $325K. The position accounts for ﹤0.01% of the portfolio, ranked #1350.

Cresset Asset Management first reported a position in GANX in Q4 2025 and has held it in 3 quarters since. The position peaked at $515K in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Cresset Asset Management held 160,000 shares of Gain Therapeutics worth $325K as of Q2 2026.
  • Cresset Asset Management left its Gain Therapeutics share count unchanged in Q2 2026.
  • Gain Therapeutics made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1350 holding.
  • Cresset Asset Management first reported a position in Gain Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Cresset Asset Management's Gain Therapeutics position peaked at $515K in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.